New institute to study RNA medicine; Alnylam adds to board of directors;

> The Cancer Center at Beth Israel Deaconess Medical Center in Boston launched a new Institute for RNA Medicine. Story

> Alnylam Pharmaceuticals ($ALNY) added Amy Schulman to its board of directors. Release

> Ophthalmology company Icon Bioscience completed enrollment of its Phase III trial for an injected, sustained-release formulation of the anti-inflammatory agent dexamethasone following cataract surgery. Release